Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma
- PMID: 32908118
- PMCID: PMC7504865
- DOI: 10.12659/MSM.925051
Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma
Abstract
BACKGROUND This study aimed to investigate the value of CA125 dynamic change in PFS prediction for patients with epithelial ovarian carcinoma (EOC). MATERIAL AND METHODS Data analysis was performed using SPSS 24.0 statistical software with progression-free survival (PFS) as an outcome measure. Kaplan-Meier method was used to analyze the relationship between PFS and preoperative and postoperative NLR, PLR and CA125 levels, CA125 half-life, CA125-negative time, age, FIGO stage, histopathology, differentiation, vessel carcinoma embolus, and ascites. The survival curves were compared by the log-rank test. Based on the results of single-factor analysis, the Cox model was used for multifactor analysis to analyze independent risk factors affecting the PFS of epithelial ovarian carcinoma. RESULTS A total of 117 patients with EOC were selected from January 2012 to January 2019 to carry out a retrospective study. Univariate analyses showed that PFS of the patients with EOC was associated with differentiation, vessel carcinoma embolus, FIGO stage, CA125 half-life, CA12- negative time, and preoperative NLR (P<0.05). Multivariate analysis by the Cox model showed that vessel carcinoma embolus, CA125 half-life, differentiation, and preoperative NLR are the independent risk factors for PFS in patients with EOC. CONCLUSIONS The serum CA125 dynamic as reflected by CA125 half-life is the most important independent prognostic factor in patients with EOC. The simplicity of CA125 monitoring and its correlation with EOC patient survival can identify patients with poor prognosis through monitoring CA125 half-life, which can provide a reference value for use in clinical practice.
Conflict of interest statement
None.
Figures
Similar articles
-
[The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].Zhonghua Zhong Liu Za Zhi. 2017 Sep 23;39(9):676-680. doi: 10.3760/cma.j.issn.0253-3766.2017.09.007. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28926896 Chinese.
-
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.J Ovarian Res. 2019 Jul 31;12(1):72. doi: 10.1186/s13048-019-0544-y. J Ovarian Res. 2019. PMID: 31362750 Free PMC article.
-
Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:364-369. doi: 10.1016/j.ejogrb.2019.07.010. Epub 2019 Jul 26. Eur J Obstet Gynecol Reprod Biol. 2019. PMID: 31400565
-
Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen.Taiwan J Obstet Gynecol. 2024 Jan;63(1):10-16. doi: 10.1016/j.tjog.2023.11.005. Taiwan J Obstet Gynecol. 2024. PMID: 38216242 Review.
-
Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis.Int J Gynecol Cancer. 2023 Dec 4;33(12):1913-1920. doi: 10.1136/ijgc-2023-004825. Int J Gynecol Cancer. 2023. PMID: 37949486
Cited by
-
The relationship between pre-operative lymphocyte to monocyte ratio and serum cancer antigen-125 among women with epithelial ovarian cancer in Lagos, Nigeria.Ecancermedicalscience. 2021 Sep 14;15:1288. doi: 10.3332/ecancer.2021.1288. eCollection 2021. Ecancermedicalscience. 2021. PMID: 34824611 Free PMC article.
-
Predicting epithelial ovarian cancer prognosis: correlation of posttreatment 18F-fluorodeoxyglucose positron emission tomography-computed tomography metabolic parameters, serum carbohydrate antigen, and human epididymis protein levels with overall survival.Quant Imaging Med Surg. 2024 Jan 3;14(1):972-985. doi: 10.21037/qims-23-859. Epub 2024 Jan 2. Quant Imaging Med Surg. 2024. PMID: 38223064 Free PMC article.
-
Evaluation of Serum Cancer Antigen (CA)-125 Levels as a Biomarker for Ovarian Lesions: Correlation With Histopathological Diagnosis and Clinical Outcomes.Cureus. 2024 Jul 25;16(7):e65342. doi: 10.7759/cureus.65342. eCollection 2024 Jul. Cureus. 2024. PMID: 39184596 Free PMC article.
-
rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.Antib Ther. 2024 Jul 8;7(3):256-265. doi: 10.1093/abt/tbae018. eCollection 2024 Jul. Antib Ther. 2024. PMID: 39262441 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- Uzan J, Bonsang-Kitzis H, Rossi L, et al. Prognostic impact of initial tumor load and intraperitoneal disease dissemination patterns in patients with advanced ovarian cancer undergoing complete cytoreductive surgery. Eur J Surg Oncol. 2019;45(9):1619–24. - PubMed
-
- Pignata S, Pisano C, Di Napoli M, et al. Treatment of recurrent epithelial ovarian cancer. Cancer. 2019;125(Suppl 24):4609–15. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous